BUSCOPAN solution controls pain associated with spasmodic colic, flatulent colic, and simple impactions in horses. BUSCOPAN works fast to relieve the pain caused by spasmodic colic, flatulent colic or simple impactions. Studies show that BUSCOPAN begins to relax gastrointestinal spasms within 5 to 10 minutes.1 And unlike NSAIDs, it won't mask the symptoms of a deteriorating colic situation, allowing a more timely prognosis to be made. It gets right to the source of pain to relieve your horse. BUSCOPAN Injectable Solution (N-butylscopolammonium bromide) is the only antispasmodic approved by the FDA for use in horses. BUSCOPAN is indicated for the control of abdominal pain (colic) associated with spasmodic colic, flatulent colic, and simple impactions in horses.

What Its For

For the control of abdominal pain (colic) associated with spasmodic colic, flatulent colic, and simple impactions in horses.

How It Works

BUSCOPAN Injectable Solution (N-butylscopolammonium bromide) works to relax the gastrointestinal smooth muscles and control pain associated with spasmodic colic. It gets right to the source of pain to relieve your horse.

Cautions/Precautions

BUSCOPAN Injectable Solution (N-butylscopolammonium bromide) is not recommended for use in nursing foals or in pregnant or lactating mares, as safety has not been established. The effects of BUSCOPAN may be potentiated by the concomitant use of other anticholinergic drugs. Studies of concomitant administration of BUSCOPAN with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy. The safety of BUSCOPAN has not been established for intramuscular (IM) administration. Administration of BUSCOPAN results in heart rate elevation. Heart rate can not be used as a valid indicator of severity of pain for 30 minutes following IV injection.

Storage

Store at or below 25°C (77°F) with excursions permitted up to 30°C (86°F). Avoid freezing. Use contents within 24 months of first puncture.

Active Ingredients

N-butylscopolammonium bromide

How Its Sold

BUSCOPAN Injectable Solution (N-butylscopolammonium bromide) is supplied in 50 mL multi-dose vials containing 20 mg N-butylscopolammonium bromide per mL.

References

1. Freedom of Information Summary NADA 141-228. Buscopan (N-butylscopolammonium bromide) on same line Boehringer-Ingelheim Vetmedica, Inc. May 2004. BUSCOPAN is a registered trademark of Sanofi-Aventis Deutschland GmbH, used under license. ©2025 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0395-2025.